Yesterday, Celgene Corporation (NASDAQ:CELG) shares were trading up 6% after posting a robust third-quarter EPS beat. Subsequently, Cantor analyst Mara Goldstein reiterates a …
In a research report published Thursday, Canaccord analyst John Newman reiterated a Buy rating on shares of Celgene Corporation (NASDAQ:CELG) with a price target …
Celgene Corporation (NASDAQ:CELG) reported net product sales of $2,969 million for the third quarter of 2016, a 28 percent increase from the same period …
Celgene Corporation (NASDAQ:CELG) announced that adult patients in England and Wales with chronic plaque psoriasis will now have access to oral OTEZLA®(apremilast) following …
In Vienna, Austria at the United European Gastroenterology Week (UEGW) Conference held from October 15th through the 19th, Celgene Corporation (NASDAQ:CELG) announced new …
Celgene Corporation (NASDAQ:CELG) and Sage Bionetworks announced a collaboration to develop an iPhone application utilizing the Apple ResearchKit framework to improve the understanding of …
By Dana Lyons A key gauge of biotechnology stocks is testing major trendline support presently – can it hold yet again? When this …
Valeant Pharmaceuticals Intl Inc Wells Fargo analyst David Maris is out today with another bearish note on Valeant Pharmaceuticals Intl Inc (NYSE:VRX). In this episode, …
Celgene Corporation (NASDAQ:CELG) and Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) announced each company has entered into collaboration agreements with Abbott (NYSE:ABT) to develop and commercialize …
Celgene Corporation (NASDAQ:CELG) announced results from multiple sponsored and independent studies will be presented during the European Society of Medical Oncology (ESMO) 2016 Annual …
